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EDITORIAL REVIEW
Tamm-Horsfall protein—uromodulin (1950—1990)
Tamm-Horsfall glycoprotein (THP) is the most abundant
protein in normal human urine. It was first described as
"urinary mucoprotein" by Morner [1] and further characterized
when Tamm and Horsfall [21 described the salt precipitation
method of isolating THP from urine and found it to be the
substance responsible for urinary inhibition of myxovirus-
induced hemagglutination. It is present in the kidneys of all
placental mammals but has not been demonstrated in marsupi-
als, monotremes, or other vertebrates [3]. THP is a major
constituent of urinary casts [4—6], and in humans, the daily
excretion ranges from 20 to 200 mg [7]. Its physicochemical and
biological properties have been studied extensively, but its
function has remained obscure [6, 81.
In 1985, another glycoprotein was independently purified
from urine of pregnant women using lectin adherence columns
and called uromodulin [9]. The carbohydrate moiety of uromod-
ulin subsumes numerous functions. It is a specific ligand for
cytokines, such as interleukin-l (IL-l), interleukin-2 (IL-2), and
tumor necrosis factor (TNF). Related oligosaccharides inhibit
in vitro T cell proliferation induced by specific antigens. Other
attached carbohydrates are responsible for inhibition of an
IL-i-dependent co-mitogenic assay. Recently, we and others
demonstrated by cDNA and amino acid sequencing that the
protein backbone of THP and uromodulin are identical [10, 11].
To emphasize the importance of glycosylation, we refer to the
glycoprotein isolated by the salt precipitation method of Tamm
and Horsfall as THP and that isolated from pregnancy urine by
lectin adherence as uromodulin [9].
Biochemistry
Urinary THP exists in a polymeric form (Mr 7 x i0 D),
which can be dissociated into monomeric molecules (Mr 80,000
D) with urea [12], 50% acetic acid [13], 6 M guanidine hydro-
chloride, and 0.05% sodium dodecyl sulfate [61. The amino acid
composition was estimated by Fletcher et al [14] and revealed
no unusual amino acids. Acidic amino acids outnumbered the
basic amino acids, giving THP a low isoelectric point.
Recent cloning and sequencing of the THP (uromodulin) gene
has essentially confirmed the amino acid composition reported
previously [10]. Uromodulin clones were isolated from a human
kidney cDNA library using oligonucleotide probes that were
synthesized based on extensive amino acid sequence data
originating from tryptic digests of THP and uromodulin. Avail-
able evidence suggests the presence of a single THP gene.
Nucleotide sequencing of a full-length cDNA predicts a protein
of 640 amino acids. This precursor protein includes a 24 amino
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acid leader sequence, which is cleaved during processing,
resulting in a mature protein with 616 amino acids including 48
cysteine residues. Hydrophobicity plotting shows that THP
does not have a classic transmembrane hydrophobic region.
This, along with the presence of a characteristic leader se-
quence, suggests that the majority of THP is in the form of a
secreted protein. However, this finding also raises an interest-
ing dilemma: evidence based on microscopic studies, ultra-
structural studies, and antibody cross-linking and capping phe-
nomena all strongly suggest that THP exists, at least in part, as
a membrane-associated protein. This makes the membrane
form of THP an excellent candidate to be anchored to lipid via
a phospholipase C-sensitive linkage as previously described for
alkaline phosphatase, 5' nucleotidase, decay accelerating fac-
tor, scrapie prion protein, the LFA-3 antigen, and the Thyl
antigen [15]. These studies for THP remain to be done. Four
separate homologous domains of THP exhibit strong similarity
to the cysteine-rich region of the epidermal growth factor
precursor [16]. This domain has been described in a number of
extracellular glycoproteins, including the LDL receptor, throm-
bomodulin, tissue plasminogen activator, and a number of
clotting factors, including Factor IX, Factor X, and protein S
[17]. Recent studies suggest that a subset of these cysteine-rich
domains acts as a consensus sequence leading to the post-
translational hydroxylation of aspartic acid and asparagine [18].
Indeed, both potential asparagines in the THP molecule are
hydroxylated. THP (uromodulin) also expresses an "RGD"
sequence previously described in a number of extracellular
matrix proteins, such as fibronectin, fibrinogen, type 1 collagen,
and thrombospondin, which bind to cell surface receptors of the
integrin superfamily [19, 20]. Thus, the THP gene contains
several conserved structural and functional domains common
to many important groups of proteins.
The carbohydrate moiety accounts for 30% of the THP
molecule by weight [4, 9]. Based on the cDNA predicted amino
acid sequence analysis, human THP has eight potential N-
linked glycosylation sites. However, analytical data suggest
that only five are utilized [21]. There is no evidence for 0-linked
sugars in human THP [22]. The carbohydrate moiety is essential
for inhibition of viral hemagglutination, the property that led to
the initial characterization of the protein by Tamm and Horsfall
[2]. This property probably resides in the nonacetylated sialic
acid component, because THP produced by hamster kidney
cells, which lacks sialic acid, and rabbit THP, which was
0-acetylated sialic acid, do not inhibit viral hemagglutination
[23, 24].
THP in solution tends to gel readily [25]; this property has
obvious implications for urinary cast formation, and intact
glycosylation appears to be important for this property. Gel
formation is increased by various factors, such as calcium and
sodium ions [25], albumin [26], radiocontrast media [27—29],
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and Bence Jones proteins [30]. It is reduced by urea [12] and by
alkaline pH [25].
THP from 90% of the Caucasian population expresses a
specific structural complex consisting of a 13-linked N-acety-
lated galactosamine; this substance, also found on red blood
cells, is known as Sd antigen and is the determinant of the Sd
blood group [31, 32]. This antigen may explain the reported
immunological cross reactivity between THP and erythrocyte
ghosts [33].
Approximately 90% of the oligosaccharides expressed on
human THP consist of complex sialylated tn- and tetra-anten-
nary chains [21]. THP also expresses the specific binding site
for L-PHA as well as polylactosamine termini measured both
structurally and by the affinity of THP for the lectin Dolichos
biflorus [34] (Fig. lA). Evidence by Serafini-Cessi, Dall'olio and
Malagolini [35] supports the earlier suggestion [22] that THP
also expresses unprocessed mannose-rich chains of the general
structure GlcNac2Man(57). High-resolution NMR data confirm
the presence of M5, M6, and M7 oligosaccharides (Fig. 1) [36].
Uromodulin, compared to THP, is rich in these unprocessed
high mannose chains. Our evidence suggests that MS,M6 car-
bohydrate residues are critical for binding to certain cytokines,
A
Fig. 1. A. Structure of idealized tetra-antennary chain of THP
demonstrating multiple lectin binding sites. Evidence [21] suggests
significant heterogeneity in these chains. B. Structure of mannose-rich
chains on THP. M5, M6, and M7 structures are based on H-nmr data [36].
D-mannose, Man or (M); D galactose, Gal; N-acetyl glucosamine, GlcNac;
N-acetyl galactosamine, GalNac; sialic acid, NANA; asparagine, asn;
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including IL-l, IL-2, and TNF. Furthermore, these same gly-
cosylation modifications are able to mimic the in vitro immu-
nomodulatory function of uromodulin [37]. Functional evidence
suggests that alterations in the carbohydrate structure may
occur in pregnancy [10]. Uromodulin, which was originally
isolated by lectin (concanavalin A) adherence columns from
human pregnancy urine based on its in vitro immunosuppres-
sive activity, is at least 10 times more immunosuppressive in
vitro than salt-precipitated THP. It appears that differential
bioactivity is not due to amino acid sequence differences, but is
likely the result of differences in glycosylation between THP
(isolated from nonpregnancy urine by salt precipitation) and
uromodulin (isolated from pregnancy urine using a lectin adher-
ence column) [10]. Alteration of THP glycosylation has also
been described in diabetes [38].
Localization
THP distribution in the body is primarily limited to the
kidney. Using Northern blot analysis of total RNA from various
rat tissues, significant message was detected only in extracts of
kidney; liver, heart, lung, brain, thymus, muscle, spleen and
testis were negative. Human placenta mRNA also lacked mes-
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eight weeks in human fetal kidney, two days pre-term in rat
[47], and three days pre-term in hamster kidney [48]. Urine
from fetal kidney contributes to amniotic fluid from 12 to 14
weeks [49]. While THP has been described in human amniotic
fluid near term by several researchers, studies in mid-term
amniotic fluid have been more equivocal [50—52]. We tested
amniotic fluid from four patients at 16 weeks and did not find
THP by an enzyme-linked immunosorbent assay in which the
lower limit of detection was 20 ng/ml (S. Kumar and P.
Schmidt, unpublished observation).
The relative abundance, specific nephronal location, and
evolutionary conservation of THP suggest that this glycopro-
tein has important physiologic functions. Until recently, the
speculation regarding the possible function of THP has re-
volved around the physiological properties of TAL. It has been
suggested that the remarkable gel-forming tendency of THP
might be responsible for the water impermeability of TAL, with
the absence of THP from macula densa serving as a window
allowing tubuloglomerular feedback to occur. Furthermore, the
presence of RGD sequence in the THP molecule makes it
possible that THP acts as an intercellular adhesion protein by
binding to integrin receptors on adjacent cell surfaces. This
alluring hypothesis remains to be tested experimentally.
Although early reports suggested that THP binds to furo-
semide [53], ethacrynic acid, and mercuric chloride [8], more
recent studies have not confirmed this finding [54]. Since these
diuretic agents act on TAL, it had been postulated that THP
may be the 2C1-K-Na co-transporter, but there is no direct
evidence for this speculation. An immunochemical study of a
variety of rat epithelia found that antiserum to THP did not
co-localize with known intracellular distribution of the 2C1-
K-Na co-transporter [55]. The uniform presence of THP on
both luminal and basolateral aspects of the TAL cells argues
against it being a protein involved in vectorial transport of ions
across the epithelium.
Better evidence is available to support a role for THP in
urothelial defense against infection, a concept first suggested by
Orskov, Ferencz and Orskov [56, 57] when they showed that E.
coli with type I fimbriae were trapped by THP. These findings
have been confirmed by other groups [58—60]. Kuriyama and
Silverblatt [59] also demonstrated that bacteria coated by THP
are less susceptible to phagocytosis by polymorphonuclear
lymphocytes compared with uncoated bacteria. This binding to
E. co/i type I pili is dependent on the mannose content of THP,
and exogenous mannose can successfully compete for it in in
vitro binding assays [56, 57].
Recent studies have markedly expanded the potential immu-
nomodulatory role of THP and suggest that this glycoprotein
may play a central role in the regulation of circulating levels and
biologic activity of several important cytokines, including IL-l,
TNF, and IL-2 [61, 62]. The original studies suggesting an
important role for this glycoprotein were performed with uro-
modulin. Uromodulin was first shown to be a high affinity ligand
for rIL-l [63], and later work demonstrated that rTNF and rIL-2
also bind specifically to uromodulin [62, 64]. Subsequent work
has shown that THP isolated by salt precipitation shares an
identical binding affinity with uromodulin. All of these studies,
however, have utilized immobilized cytokines as a capture
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Fig. 2. Distribution of THP in the human nephron is limited to the thick
ascending limb and the early distal convoluted tubule. THP is absent
from the macula densa.
sage [10]. Within the kidney, THP is specifically localized (Fig.
2) to the epithelial cells of the thick ascending limbs (TAL) of
the loops of Henle and the most proximal part of the distal
convoluted tubule, which is thought to be embryologically and
functionally similar to the TAL [39, 40]. This protein is char-
acteristically absent from macula densa and from glomeruli,
proximal convoluted tubules, thin limbs of the loops of Henle,
collecting duct, blood vessels, and the interstitium [41, 42]. On
immunoelectron microscopy, THP is found in both luminal and
basolateral aspects of the cell membrane and in the membranes
of Golgi apparatus and endoplasmic reticulum [8, 41]. Small
quantities of THP can be detected in blood by sensitive immu-
noassays [8, 43, 44]. The finding of THP immuno-cross-reactive
material from liver and cerebrospinal fluid using antisera to
THP has been interpreted to suggest that THP might be present
extrarenally in all tissues involved in active chloride transport
[45], but these studies have not been confirmed using monoclo-
nal antibodies [42], nor has mRNA for THP been detected in
these tissues [10]. However, the renal environment appears not
to be essential for transcription of the THP gene and for
synthesis of this protein. Pieces of rat renal cortex and medulla,
when transplanted to the anterior chamber of the eye, prolifer-
ate to form tubule-like structures [46]. Sections of these im-
plants reacted with monoclonal antibodies specific for rat THP
using an immunoperoxidase technique (S. Kumar and M. Celio,
unpublished observation).
Developmentally, the appearance of THP coincides with
maturation of the thick ascending limb of Henle's loop. Immu-
nohistochemical studies have demonstrated its presence at
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reagent. Moonen and colleagues attempted to reproduce these
studies with both uromodulin and TNF in solution. These
authors found that rTNF and uromodulin in solution only bound
to each other at a pH below 6.0 with optimal interaction
occurring at pH 5.0, conditions likely to be found in the distal
tubule [65]. Furthermore, these authors suggested that TNF
might be inactive under these conditions, but more recent
studies suggest that TNF might actually have enhanced activity
at a low pH [66]. In all cases, these cytokines are binding to
specific carbohydrate sequences found on THP. This conclu-
sion is based on four different experimental approaches. First,
oxidative destruction of exposed carbohydrates on THP or
enzymatic removal with N-glycanase destroys the ability of
THP to bind to cytokines [63]. Second, defined mono- and
disaccharides specifically compete with THP for binding to
immobilized IL-l, TNF, and IL-2 [62, 64]. Third, defined plant
lectins, such as concanavalin A and wheat germ agglutinin,
compete with IL-i and TNF for binding to the carbohydrate
moiety of THP [62]. Finally, using a panel of IL-i /3 analogues
engineered by site-specific mutagenesis and differing from one
another by a single amino acid substitution, we have developed
evidence that IL-l f3 has two different binding domains (A.
Muchmore and A. Shaw, unpublished observation). One bind-
ing domain is lectin-like and binds specifically to carbohydrate
expressed by THP; the alterations of this site affect binding to
THP but do not affect binding of IL- 1 to the 80-kD, cell surface
IL-l receptor that was first described by Dower et al [67].
Conversely, substitutions at the cell surface receptor binding
site affect cell binding but do not alter binding to THP [67, 68].
Immunohistochemical studies demonstrate that exogenous
rIL-l and rTNF bind to renal tubular segments that express
THP, namely TAL. Mutant IL-i that fails to bind to the
carbohydrate domain of THP in vitro also fails to bind to the
renal tubule sections (A. Muchmore, unpublished observation).
Most studies that have examined the in vivo administration of
'25l-labeled rIL-l, rTNF, or rIL-2 demonstrate that the kidney
is the major organ responsible for the rapid (Tl/2 on average of
5 to 10 minutes) plasma clearance of these cytokines (A.
Muchmore, unpublished observation) [69—72]. However, some
studies show more widespread tissue distribution, with the
kidney being only one of several organs responsible for uptake
[73]. In aggregate these observations suggest that THP ex-
presses carbohydrate moieties recognized by a number of
cytokines and that the interaction between THP and these
cytokines is optimal at an acidic pH. Since the kidney appears
to be a major site of cytokine catabolism, these studies offer a
potential mechanism which deserves further study.
The immunoregulatory role of THP has been somewhat
controversial. Early results suggested that THP induced T cell
proliferation [74], while later studies found that THP inhibited
lectin-induced proliferation and the mixed lymphocyte response
[75]. These authors found that the immunoregulatory activity of
THP resides in the carbohydrate moiety. Our own studies using
uromodulin demonstrate that it inhibits T cell proliferation in
assays of IL-i-induced proliferation and antigen-specific prolif-
eration [10]. However, neither THP nor uromodulin blocks the
ability of IL- 1 to act directly on fibroblasts to induce prosta-
glandin synthesis (A. Muchmore, unpublished observation).
Furthermore, uromodulin fails to block binding of IL-i to its
cell surface receptor (K. Matsushima and J. Oppenheim, per-
sonal communication). This is consistent with the observation
that the uromodulin binding site on rIL-l /3 is physically distinct
from the EL-4 murine binding site of rIL-l. Studies using an
IL-l co-mitogenic assay demonstrate that excess phytohemag-
glutinin (PHA), but not excess IL-l, will overcome inhibition
mediated by either uromodulin or THP. Thus, although immo-
bilized IL-I binds to uromodulin with a very high affinity,
inhibition in the IL-l co-mitogenic assay is the result of com-
petition with PHA and not with IL-l. These results confirm the
hypothesis of Serafini-Cessi et al [76], who suggested that THP
might compete for a cell surface lectin (PHA) binding site.
Interestingly, oligosaccharides that inhibit the IL-l/PHA co-
mitogenic assay fail to inhibit T cell proliferation induced by
specific antigen and vice versa. We have purified the oligosac-
charides derived from pregnancy THP (uromodulin) responsi-
ble for inhibition of antigen-specific proliferation and structur-
ally characterized them using high resolution nuclear magnetic
resonance (A. Sherblom, H. van Halbeek, and A. Muchmore,
unpublished data). These homogenous high-mannose oligosac-
charides inhibit antigen-specific proliferation at concentrations
of approximately 50 LM. Closely related oligosaccharides di-
rectly compete with uromodulin for binding to rIL-l, rTNF, and
rIL-2 at concentrations as low as 500 nM. PHA-binding oh-
gosaccharides (responsible for inhibition of the IL-i co-mito-
genic assay) fail to inhibit either the antigen-specific T cell
proliferative assay or the lymphokine binding assay. These data
suggest that oligosaccharides isolated from uromodulin have
multiple functions.
Significance of THP in disease states
Interstitial deposits of THP have been found in obstructive
uropathy [77], rejecting renal transplants [78, 79] and in neph-
ronothiasis [80, 81]. These deposits are thought to occur
through leakage of THP from rupture of obstructed or damaged
tubules. However, these deposits do not show consistent cor-
relation with inflammatory reaction and their significance in
pathogenesis of tubulo-interstitial scarring is doubtful [82].
Deposits of THP have also been demonstrated in the glomerular
mesangium in experimental models of vesico-ureteric reflux in
rats, suggesting a possible involvement of THP in glomerular
scarring associated with reflux nephropathy [83], but more
direct evidence for this hypothesis is lacking.
Injection of THP in rats leads to an inflammatory reaction
around the TAL [841. There is evidence that this reaction is
elicited by in situ formation of immune complexes. In animals
passively immunized with anti-THP antibodies, these com-
plexes are cleared more quickly [85]. Similar rabbit models of
THP-induced tubulo-interstitial nephritis have also been devel-
oped [86, 87], but there is no known human disease counterpart
to these experimental conditions.
THP has been conclusively shown to be present in the core of
renal stones [88]. However, it is not clear whether it is an
innocent bystander or an active participant in stone formation.
In vitro assays of calcium stone growth have produced varied
results. Some have shown THP to inhibit stone growth [89—93],
while others have shown promotion [94, 95], and yet others
have shown no effect [96]. We studied this effect in a "C
calcium oxalate seed crystal growth assay and found that THP
had no effect on calcium oxalate crystal growth [97]. Interest-
ingly, Keutel [98], who had provided some of the early evidence
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for the presence of THP in stones, also reported failure to
detect THP in the urine of African Blacks and related this
finding to the reported low incidence of renal stones in this
population [99]. We tested the urine of five Black Africans by
ELISA employing a monoclonal antibody to THP and detected
normal quantities of THP (S. Kumar, unpublished observation).
THP is a major constituent of urinary casts. Conditions
promoting polymerization of THP stimulate cast formation.
Experimental and clinical evidence suggests that tubular ob-
struction by urinary casts contributes to development and
maintenance of acute renal failure [reviewed in 100, 101]. In
vitro studies have demonstrated increased aggregability of THP
with Bence Jones protein and radiocontrast media [27—30]. In
cast nephropathy associated with multiple myeloma, THP has
been demonstrated in Bowman's space, suggesting reflux of
urine in a nephron obstructed distally by a cast [102]. In infants
and children with prolonged nephrograms after intravenous
urography, large amounts of THP were found in urine during
subsequent diuresis. In one infant who died of anuric renal
failure after a dye study, autopsy showed proteinaceous casts
plugging renal tubules [103]. THP polymerization in the tubules
may well be the pathophysiological basis of acute renal failure
seen after radiocontrast dye studies in patients with multiple
myeloma and/or volume depletion [104]. Maintenance of high
urine volume and urinary alkalization should theoretically pre-
vent intratubular cast formation and may be the reason why
fluid therapy has been found to be beneficial in acute renal
failure associated with use of radiocontrast media [1051 and
methotrexate [106], especially since the pharmacokinetics of
methotrexate itself have been shown not to be altered either by
hydration [1071 or by alkalization [106].
Conclusions
Although its specific nephronal location and gel-forming
characteristics have long suggested a role for THP in renal salt
and water transport physiology, this hypothesis remains uncon-
firmed. Our knowledge of the molecular biology of THP has
recently undergone rapid advancement. The complete amino
acid sequence deduced from a cDNA sequence is now avail-
able. THP (uromodulin) isolated from pregnant women is a
potent immunoregulatory molecule. THP from both pregnant
and nonpregnant sources has been shown to be a specific ligand
for a number of potent cytokines, including Il-I, TNF, and IL-2.
Both the binding activity to cytokines and the biologic activity
of THP are critically dependent upon unique glycosylation
patterns. It is possible that THP could play an important role in
the regulation of circulating levels and potentially the intrarenal
bioactivity of many important cytokines. In conclusion, it is
interesting to note that the role of THP carbohydrate and its
ability to interact with lectin-like molecules responsible for
myxovirus-induced hemagglutination were used in 1950 to first
purify this glycoprotein. It would appear that, 40 years later,
research has come full circle and again stresses the importance
of post-translational changes for this most interesting glycopro-
tein.
SATISH KUMAR and ANDREW MUCHMORE
Chicago, Illinois and Bethesda, Maryland, USA
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